Search
Thiothixene
go.drugbank.com/drugs/DB01623ApprovedA thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Benralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction.
Megestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approvedA progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor.
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[L53798] Later the same year, it was approved in the US for the same indication. [L54216]
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalTofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative.
Bendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalThrough this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death.
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnIron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnThis drug presented different dosages and it was administered as a capsule or suspension. … It was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.